Toxicity of bevacizumab in combination with chemotherapy in older patients

Oncologist

Volumn 18, Issue 4, 2013, Pages 408-414

  Mohile, Supriya G ^a   Hardt, Molly ^b   Tew, William ^c   Owusu, Cynthia ^d   Klepin, Heidi ^e   Gross, Cary ^f   Gajra, Ajeet ^g   Lichtman, Stuart M ^c   Feng, Tao ^h   Togawa, Kayo ^h   Ramani, Rupal ^h   Katheria, Vani ^h   Hansen, Kurt ^h   Hurria, Arti ^h  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^h CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Bevacizumab; Chemotherapy; Drug toxicity; Geriatric assessment; Health services for the aged

Indexed keywords

BEVACIZUMAB;

AGED; ARTICLE; CANCER CHEMOTHERAPY; COMORBIDITY; DAILY LIFE ACTIVITY; DIGESTIVE SYSTEM PERFORATION; GERIATRIC ASSESSMENT; HUMAN; HYPERTENSION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; METASTATIC COLORECTAL CANCER; NEUTROPENIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBOSIS; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA, NON-SMALL-CELL LUNG; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; NEOPLASM STAGING; PROSPECTIVE STUDIES;

EID: 84877047276     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0351     Document Type: Article

References (29)

1. Jemal A, Siegel R, Xu J et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Hurwitz H, Fehrenbacher L,NovotnyWet al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
3. Ramalingam SS, Dahlberg SE, Langer CJ et al. Outcomes for elderly, advanced-stage non-smallcell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: Analysis of eastern cooperativeoncologygrouptrial 4599. J Clin Oncol 2008;26:60-65.
4. Leighl NB, Zatloukal P, Mezger J et al. Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer in the phase III BO17704 study (AVAiL). J Thorac Oncol 2010;5:1970-1976.
5. Reck M, von Pawel J, Zatloukal P et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous nonsmall- cell lung cancer: Results from a randomised phaseIII trial (AVAiL). AnnOncol 2010;21:1804-1809.
6. Laskin J, Crinò L, Felip E et al. Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: Safety of avastin in lung trial (MO19390). J Thorac Oncol 2012;7:203-211.
7. Scappaticci FA, Skillings JR, Holden SN et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007;99:1232-1239.
8. Kabbinavar FF, Hurwitz HI, Yi J et al. Additionofbevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: Pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol 2009;27:199-205.
9. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-smallcell lung cancer. N Engl J Med 2006;355:2542-2550.
10. McKibbin T, Frei CR, Greene RE et al. Disparities in utilization of irinotecan (IRI), oxaliplatin (OX), and bevacizumab (BEV) among young and elderly patients with advanced colorectal cancer (CRC). Paper presented at 2008 Gastrointestinal Cancers Symposium; 2008.
11. François E, Guérin O, Follana P et al. Use of bevacizumab in elderly patients with metastatic colorectal cancer: Review. J Geriatr Oncol 2011;2:64-71.
12. Rodin MB, Mohile SG. A practical approach to geriatric assessment in oncology. J Clin Oncol 2007; 25:1936-1944.
13. Hurria A, Togawa K, Mohile SG et al. Predicting chemotherapytoxicity in older adults with cancer:A prospective multicenter study. J Clin Oncol 2011; 29:3457-3465.
14. Kanesvaran R, Li H, Koo K-N et al. Analysis of prognostic factors of comprehensive geriatric assessment and development of a clinical scoring system in elderly Asian patients with cancer. J Clin Oncol 2011;29:3620-3627.
15. Caillet P, Canoui-Poitrine F, Vouriot J et al. Comprehensive geriatric assessment in the decision- making process in elderly patients with cancer: ELCAPA study. J Clin Oncol 2011;29:3636-3642.
16. Hurria A, Gupta S, ZaudererMet al. Developing a cancer-specific geriatric assessment. Cancer 2005;104:1998-2005.
17. Karnofsky D, Burchenal J. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM,ed. Evaluation of Chemotherapeutic Agents. New York: Columbia University Press, 1948:191-205.
18. Podsiadlo D, Richardson S. Thetimed"Up&Go": A test of basic functional mobility for frail elderly persons. JAmGeriatr Soc 1991;39:142-148.
19. Kawas C, Karagiozis H, Resau L et al. Reliability of the Blessed Telephone Information-Memory-Concentration Test. J Geriatr Psychiatry Neurol 1995;8: 238-242.
20. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. 2010. Available at http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed June 13, 2012.
21. National Institutes of Health. FDA Approval for Bevacizumab-National Cancer Institute. 2009. Available at http://www.cancer.gov/cancertopics/druginfo/fda-bevacizumab. Accessed June 13, 2012.
22. Giantonio BJ. Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second- and third-line settings. Semin Oncol 2006;33(suppl 10): S15-S18.
23. Bekaii-Saab T, Bendall J, Cohn A. Initial results from ARIES, a multi-indication bevacizumab (BV) observational cohort study (OCS): Characteristics of metastatic colorectal cancer (mCRC) patients (pts) receiving BV and chemotherapy (CT) in 2nd line. J Clin Oncol 2008;26(suppl 15):15002.
24. Saltz LB, Clarke S, Díaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 2008;26:2013-2019.
25. Allegra CJ, Yothers G, O'Connell MJ et al. Initial safety report ofNSABPC-08:Arandomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 2009;27: 3385-3390.
26. Meyerhardt JA, Li L, Sanoff HK et al. Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer. J Clin Oncol 2012;30:608-615.
27. Sud R, Khorana AA. Cancer-associated thrombosis: Risk factors, candidate biomarkers and a risk model. Thromb Res 2009;123(suppl 4):S18-S21.
28. Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: A meta-analysis. JAMA 2011;305:487-494.
29. Kozloff M, Yood MU, Berlin J et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: The BRiTE observational cohort study. The Oncologist 2009;14:862-870.